Eisai Co., Ltd. is investigating E0302 (mecobalamin) for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a long-term study. The ALS market is characterized by a high unmet need, with limited effective therapies currently available. The successful completion of this study may position Eisai favorably against competitors, particularly in the context of emerging therapies targeting neurodegenerative diseases. Given the aging population and increasing incidence of ALS, the potential market for E0302 could be significant, contingent on positive safety and efficacy outcomes. Diligence should focus on the competitive landscape, particularly regarding ongoing trials and emerging therapies in the ALS space.